4//SEC Filing
ABERNETHY MATT 4
Accession 0000914475-25-000020
CIK 0000914475other
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 5:31 PM ET
Size
9.3 KB
Accession
0000914475-25-000020
Insider Transaction Report
Form 4
ABERNETHY MATT
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-01-31+2,436→ 33,964 total - Sale
Common Stock
2025-01-31$152.87/sh−1,283$196,136→ 32,681 total - Exercise/Conversion
Restricted Stock Unit
2025-01-31−2,436→ 2,437 total→ Common Stock (2,436 underlying)
Footnotes (4)
- [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.94 to $153.63. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F4]This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,436 shares on January 31, 2023, vested as to 2,436 shares on January 31, 2024, vested as to 2,436 shares on January 31, 2025, and will vest as to 2,437 shares on January 31, 2026, subject to the terms and conditions of the award.
Documents
Issuer
NEUROCRINE BIOSCIENCES INC
CIK 0000914475
Entity typeother
Related Parties
1- filerCIK 0001724097
Filing Metadata
- Form type
- 4
- Filed
- Feb 3, 7:00 PM ET
- Accepted
- Feb 4, 5:31 PM ET
- Size
- 9.3 KB